AngioSoma, Inc. (OTCMKTS:SOAN) Files An 8-K Entry into a Material Definitive Agreement

AngioSoma, Inc. (OTCMKTS:SOAN) Files An 8-K Entry into a Material Definitive Agreement

Story continues below

ITEM 1.01 Entry into a Material Definitive Agreement.

Effective February 21, 2017, AngioSoma, Inc.s wholly owned
subsidiary, AngioSoma Research, Inc., a Texas corporation,
entered into a Placement Agent and Advisory Services Agreement
(the Agreement) with Boustead Securities, LLC, a California
limited liability company. A copy of the Agreement is attached as
Exhibit 99.1 to this Form 8-K.

Section 3 Securities and Trading Markets

ITEM 3.02 Unregistered Sales of Equity
Securities.

In connection with the Placement Agent and Advisory Services
Agreement described in Item 1.01, AngioSoma, Inc. will issue
1,000,000 restricted shares of common stock to Boustead
Securities, LLC or its designee(s).

The shares will be issued without registration in reliance on the
exemption in Section 4(a)(2) of the Securities Act of 1933 and
Rule 506(b) of Regulation D thereunder. We believe the exemption
is available because of the substantial preexisting relation with
the parties and the offering was made solely and only to the
parties without any public offering or solicitation.

Section 8 Other Events

ITEM 8.01 Other Events.

AngioSoma, Inc. has moved its principal office to 2500 Wilcrest
Drive, 3rd Floor, Houston, Texas 77042.

Section 9 Financial Statements and Exhibits

ITEM 9.01 Financial Statements and Exhibits.

EXHIBIT NO.

DESCRIPTION

Exhibit 99.1

Placement Agent and Advisory Services Agreement dated
February 21, 2017 by and between AngioSoma, Incs
wholly-owned subsidiary, AngioSoma Research, Inc., and
Boustead Securities, LLC.


AngioSoma, Inc. (OTCMKTS:SOAN) Recent Trading Information

AngioSoma, Inc. (OTCMKTS:SOAN) closed its last trading session up +0.0001 at 0.0600 with shares trading hands.

An ad to help with our costs